Two years after the FDA placed partial clinical hold, Avidity can resume research of del-desiran as a treatment for myotonic ...

The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Avidity Biosciences, Inc. surges on positive developments in AOCs for muscular disorders, strategic partnerships, and ...

Patients with myotonic dystrophy have smaller hearts, and lower systolic and diastolic blood pressures and pulse rates. They have impaired autonomic reflexes, measured by orthostatic, Valsalva ...

Avidity Biosciences (RNA) announced the FDA has removed the partial clinical hold on delpacibart etedesiran, an investigational ...

Jackie Zabezhinsky would spend two months at the NICU at Children's Minnesota and then underwent testing and treatment for nearly a year before doctors diagnosed her with myotonic dystrophy ...

Top 2024 stock market performers include several health care stocks with unique catalysts, as well as a satellite-based ...

Corinne Johnson, an analyst from Goldman Sachs, has initiated a new Buy rating on Avidity Biosciences (RNA). Corinne Johnson’s rating is ...

Bradford City Hall and City Park Fountains were lit up in green on Sunday, September 15 for International Myotonic Dystrophy Awareness Day. Businesses and members of the public had been asked to ...